Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | BCL2 | P10415 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7813623 | 0.82 | CYP3A4 (0.43) | CYP2D6CYP3A4CYP2C9CYP2C19BCL2 | |
| SCHEMBL5099673 | 0.81 | CYP3A4 (0.42) | CYP2D6CYP3A4CYP2C9CYP2C19BCL2 | |
| SCHEMBL11836940 | 0.80 | CYP3A4 (0.44) | CYP2D6CYP3A4CYP2C9CYP2C19BCL2 | |
| SCHEMBL6048472 | 0.79 | SIGMAR1 (0.58) | CYP2D6BCL2LMNASIGMAR1CHRM4 | |
| SCHEMBL1984793 | 0.78 | BCL2 (0.41) | CYP2D6BCL2LMNAHTTNPSR1 | |
| SCHEMBL2009309 | 0.78 | BCL2 (0.62) | BCL2KMT2AL3MBTL1LMNAHTT | |
| SCHEMBL2006125 | 0.77 | CHRM4 (0.56) | CYP2D6BCL2LMNASIGMAR1CHRM4 | |
| SCHEMBL7470891 | 0.74 | KCNN4 (0.38) | CYP2D6CYP3A4CYP2C9CYP2C19USP2 | |
| SCHEMBL11868000 | 0.74 | BCL2 (0.49) | CYP2D6BCL2KMT2AL3MBTL1LMNA | |
| SCHEMBL11025495 | 0.74 | CYP3A4 (0.50) | CYP2D6CYP3A4CYP2C9CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12338204-B2 | Substituted bisphenylalkylurea compounds and methods of treating breast cancer | TEXAS TECH UNIVERSITY SYSTEM (US) | 2025-06-24 | — | — | US | disclosed |
| US-20250154098-A1 | SUBSTITUTED BISPHENYLALKYLUREA COMPOUNDS AND METHODS OF TREATING BREAST CANCER | UNIV TEXAS TECH SYSTEM (US) | 2025-05-15 | — | — | US | disclosed |
| US-20230382850-A1 | SUBSTITUTED BISPHENYLALKYLUREA COMPOUNDS AND METHODS OF TREATING INFLAMMATORY CONDITIONS | TEXAS TECH UNIVERSITY SYSTEM (US) | 2023-11-30 | — | — | US | disclosed |
| US-20210309607-A1 | SUBSTITUTED BISPHENYLALKYLUREA COMPOUNDS AND METHODS OF TREATING BREAST CANCER | TEXAS TECH UNIVERSITY SYSTEM (US) | 2021-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12338204-B2 | Substituted bisphenylalkylurea compounds and methods of treating breast cancer | TP53, ULK1, TFEB | CYP2D6 3406/4885CYP3A4 2955/4885CYP2C9 3773/4885 |
| US-20210309607-A1 | SUBSTITUTED BISPHENYLALKYLUREA COMPOUNDS AND METHODS OF TREATING BREAST CANCER | TP53, ULK1, TFEB | CYP2D6 3406/4885CYP3A4 2955/4885CYP2C9 3773/4885 |
| US-20230382850-A1 | SUBSTITUTED BISPHENYLALKYLUREA COMPOUNDS AND METHODS OF TREATING INFLAMMATORY CONDITIONS | TFEB, TP53, BECN1 | CYP2D6 3700/4885CYP3A4 3103/4885CYP2C9 3992/4885 |
| US-20250154098-A1 | SUBSTITUTED BISPHENYLALKYLUREA COMPOUNDS AND METHODS OF TREATING BREAST CANCER | TP53, ULK1, TFEB | CYP2D6 3406/4885CYP3A4 2955/4885CYP2C9 3773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.